Highest value for AMRN is a sale of the company with Europe and the US markets intact. Unless or until a deal for Europe is closed, it will keep open the prospect of a sale of the entire company. The $460 million raise actually increased the odds of a takeover as a Europe deal is not needed to launch in the US in an effective way. Obviously, AMRN will not GIA in Europe. They will either sell the company or do a distribution deal for Europe.
They can only sell Europe if the BOD believe they will not get bought out. If they sell Europe now /when approved they are going to drastically restrict buy out potential and price. do we not loose sight of fundamentals in this reaction to day to day SP- ? an incredible drug and incredible market -an incredible future - either GIA....but expect that will always have ups and downs but nonetheless from here and soon an upward path-ultimate SP 50/75/100/150?? or BO for a far greater market cap than now - 20B/30B/50B more ? One or other will happen - this drug can not and will not fail The company holding it - Amarin or BP will do very very well - so will shareholders We have been on a long road ... it will be a while longer yet but faith and patience will be rewarded
News 
Market Data 
Discover 
AI
